Other substances

Lercanidipine

A dihydropyridine calcium channel blocker.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

2
 Supporting references
0
 Contradictory references
2
 AI-suggested references
54
 Clinical trials

General information

Lercanidipine is a dihydropyridine calcium channel blocker. It acts as a peripheral vasodilator and is therefore used for treatment of hypertension and in some types of angina (DrugBank).

Lercanidipine on PubChem
Lercanidipine on Wikipedia

Marketed as

CARDIOVASC; CARMEN; CORIFEO; LERCANIL; LERCATON; LERZAM; RENOVIA; VASODIP; ZANDIP; ZANICOR; ZANIDIP

 

Structure image - Lercanidipine

CC1=C(C(C(=C(N1)C)C(=O)OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC

Supporting references

Link Tested on Impact factor Notes Publication date
Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19
Preprint Screening 		VERO cells

Hydrochloride salt

 Mar/19/2020
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2
3CLpro Small molecule Enzyme assay In vitro 		in vitro enzyme assay 3.75

Inhibited the SARS-CoV-2 3C-like protease in vitro with IC50 of 16.2 μM.

 Oct/25/2020

AI-suggested references

Link Publication date
Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma.
Jan/19/2022
Treatment of Focal and Segmental Glomerulosclerosis Secondary to High Altitude Polycythemia with Acetazolamide.
Apr/08/2022

Clinical trials

ID Title Status Phase Start date Completion date
NCT05184114 Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance Recruiting Not Applicable Oct/04/2021 Jun/30/2023
  • Alternative id - UW 21-005
  • Interventions - Diagnostic Test: Cardiac Magnetic Resonance, Blood Tests
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - The University of Hong Kong, Hong Kong, Hong Kong
  • Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic
  • Enrollment - 162
  • Age - Child, Adult, Older Adult
  • Outcome measures - The extent of myocardial involvement, as assessed by CMR tissue characterisation (T1/ T2/ ECV/ LGE), 2 weeks after patient recovery, at 3-months post discharge and at 1-year post discharge.|The correlation of these myocardial characteristics to biventricular structure, function (CMR cine/strain), blood biomarkers of inflammation, clinical symptoms, and functional capacity (6 minute walk test) at all time-points|Number of Participants with followed-up beyond the end of this study to assess for hard outcomes such as death.|Number of Participants with followed-up beyond the end of this study to assess for hard outcomes such as heart failure hospitalisation.|Number of Participants with cardiac arrest.|Number of Participants with ventricular tachycardia.|Number of Participants with ventricular fibrillation.|Rate of subclinical myocardial inflammation post COVID-19 vaccination.
NCT04359927 Long-term Effects of Coronavirus Disease 2019 on the Cardiovascular System: CV COVID-19 Registry Recruiting Apr/20/2020 Aug/31/2025
  • Alternative id - HCB/2020/0457
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Hospital Clínic of Barcelona, Barcelona, Catalonia, Spain
  • Study designs - Observational Model: Case-Control|Time Perspective: Cross-Sectional
  • Enrollment - 10000
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Cardiovascular mortality|Acute myocardial infarction|Stroke
NCT04376853 CoronaWatch - Early Detection of Cardiovascular Risks in COVID-19 Via SmartWatch Recruiting Apr/15/2020 Jul/01/2020
  • Alternative id - CoronaWatch
  • Interventions - Device: Apple Watch Series 5
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Department III of Internal Medicine, University Hospital Heidelberg, Heidelberg, Baden-Württemberg, Germany
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 50
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Biomarker|Protective factors|SmartWatch compliance|Arrhythmias|QT time changes|Longitudinal risk models
NCT05081362 Cardiovascular Assessment in Patient Recovered From COVID-19 and Recovery of Autonomic Nervous System in Association With the Severity of the Disease Recruiting Not Applicable Oct/18/2021 Oct/06/2022
  • Alternative id - COVIDans
  • Interventions - Other: Non invasive cardiovascular monitoring with CNAP device of arterial pressure, ECG and respiratory activity
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - IRCCS Policlinico San Donato, San Donato Milanese, Milano, Italy
  • Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care
  • Enrollment - 90
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Arterial pressure measured in mmHg|Heart rate measured in bpm|Respiratory frequency
NCT04644341 Tele-monitoring of COVID-19 Survivors for Long-Term Impacts Recruiting Jan/15/2021 Nov/01/2021
  • Alternative id - B2020:114 (HS24395)
  • Interventions - Combination Product: cardiovascular and respiratory systems monitoring
  • Study type - Observational
  • Study results - No Results Available
  • Locations - University of Manitoba, Winnipeg, Manitoba, Canada
  • Study designs - Observational Model: Case-Only|Time Perspective: Retrospective
  • Enrollment - 20
  • Age - 18 Years to 90 Years   (Adult, Older Adult)
  • Outcome measures - Blood pressure|Breathing sounds average power|Risk of aspiration|SaO2 level|Montreal Cognitive Assessment (MoCA)
NCT04426084 Cardiovascular Risk Factors and Severe COVID-19. A Nationwide Registry-based Case-Control Study Active, not recruiting Mar/01/2020 Dec/31/2022
  • Alternative id - 4
  • Interventions - Other: Hypertension|Other: Diabetes type 2|Other: Obesity|Drug: Antihypertensive Agents|Drug: Statins (Cardiovascular Agents)
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Södersjukhuset, Stockholm, Sweden
  • Study designs - Observational Model: Case-Control|Time Perspective: Other
  • Enrollment - 22784
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Severe Covid-19|Severe Covid-19 with pulmonary embolism|CRRT(Continuous Renal Replacement Therapy)|ECMO (Extracorporeal Membrane Oxygenation )|ICU Mortality
NCT04430374 Registry for a Cardiovascular Patient Who COVID-19 Infection in Qatar and Gulf Recruiting Jun/02/2020 Dec/31/2020
  • Alternative id - MRC-05-113
  • Interventions - Other: No interverntion
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Hamad Medical Corporation, Doha, Unlisted (UL), Qatar
  • Study designs - Observational Model: Cohort|Time Perspective: Other
  • Enrollment - 100
  • Age - Child, Adult, Older Adult
  • Outcome measures - The impact of COVID-19 on cardiovascular patient
NCT04606732 CardioVascular Disease Progression and Prognosis in COVID-19 Recruiting Sep/20/2020 Dec/31/2021
  • Alternative id - CV_SPP_COVID19
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Policlinico Sant'Orsola, Bologna, Italy
  • Study designs - Observational Model: Cohort|Time Perspective: Cross-Sectional
  • Enrollment - 2000
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Mortality
NCT04756193 Evaluate Long Term Cardiovascular and Pulmonary Complications After COVID-19 With Point of Care Ultrasound Recruiting Apr/15/2021 Dec/31/2022
  • Alternative id - 20.0836
  • Interventions - Diagnostic Test: Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound
  • Study type - Observational
  • Study results - No Results Available
  • Locations - University of Louisville Health, Louisville, Kentucky, United States
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 250
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Echocardiographic strain measurements of the left, right heart|Lung ultrasound measurements
NCT04555187 Cardiovascular Risk Stratification in Covid-19 Active, not recruiting Jun/08/2020 Dec/01/2022
  • Alternative id - STUDY00021368
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Oregon Health and Science University, Portland, Oregon, United States
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 60000
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number and rate of persons with cardiovascular composite outcome|Rate of all-cause death outcome|Rate of cardiac arrhythmia
NCT04371289 Predictors of Cardiovascular Risk in Covid-19 Patients During Acute Disease and at Short Term Follow-up Active, not recruiting Apr/08/2020 Sep/10/2021
  • Alternative id - CE_2020_03_26_02
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Istituto Auxologico Italiano, Milan, Italy
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 5500
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Predictive modeling of in-hospital outcome|Clinical, pathophysiological and molecular mechanisms|Short -Term Sequelae
NCT04325867 Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19 Unknown status Not Applicable Mar/31/2020 Oct/01/2020
  • Alternative id - GTP0032
  • Interventions - Other: Tele-medicine platform
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Medical Sciences Academy, Bucharest, Romania|University of Medicine and Pharmacy Gr T Popa, Iasi, Romania
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research
  • Enrollment - 200
  • Age - Child, Adult, Older Adult
  • Outcome measures - Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients|Number of patients included in this platform|Number of consultations/sessions given
NCT04823182 Study of HEarT DiseAse and ImmuNiTy After COVID-19 in Ireland Active, not recruiting Feb/16/2021 Sep/22/2022
  • Alternative id - SETANTA_Study_Protocol_V2.0
  • Interventions - Diagnostic Test: Cardiovascular Magnetic Resonance Imaging
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Cardiovascular Research Institute Dublin, Dublin, Ireland
  • Study designs - Observational Model: Case-Only|Time Perspective: Prospective
  • Enrollment - 100
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Left ventricular (LV) ejection fraction|LV end diastolic volume|Right ventricular ejection fraction|Native T1, T2|Late gadolinium enhancement|Pericardial abnormalities|Immunity parameters|Markers of coagulation and endothelial cell activation
NCT04435457 Cardiovascular Implications of COVID-19 Active, not recruiting Sep/01/2020 Apr/30/2022
  • Alternative id - STU-2020-0359
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - University of Texas Southwestern Medical Center, Dallas, Texas, United States
  • Study designs - Observational Model: Cohort|Time Perspective: Cross-Sectional
  • Enrollment - 70
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Prevalence of Myocarditis|Prevalence of cardiac abnormalities by cardiac magnetic resonance imaging|Prevalence of molecular and genetic immune system abnormalities
NCT04435015 The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications Not yet recruiting Phase 1|Phase 2 Nov/01/2021 Dec/31/2021
  • Alternative id - 2000028279
  • Interventions - Drug: Camostat Mesylate|Drug: Microcrystalline Cellulose, NF
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 200
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Percent change in plasma D-Dimer|Overall Safety and adverse event|Change in plasma Fibrinogen levels|Change in plasma troponin|New onset cardiomyopathy|Duration of intubation|Length of stay in the intensive care unit|Time to discharge from hospital|Occurrence of major adverse cardiovascular events
NCT04724707 Russian Cardiovascular Registry of COVID-19 Recruiting Sep/11/2020 Dec/01/2022
  • Alternative id - 0509-20-2020
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Almazov National Medical Research Centre, Saint Petersburg, Russian Federation
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 900
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Death|Hospitalization for cardiovascular reasons|Hospitalization for any reason|Time to death|Mechanical support or heart transplant|ICD or CRT|Quality of life|Cardiac pacing or catheter ablation|Syncope or presyncope|Arrythmias
NCT04624503 Prognostic and Clinical Impact of Cardiovascular Involvement in Patients With COVID-19 Recruiting Oct/01/2020 Oct/01/2021
  • Alternative id - CARDIOCOVID
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Humanitas Research Hospital, Rozzano, Milan, Italy|Centro Cardiologico Monzino, Milan, Italy|IRCCS Auxologico San Luca, Milan, Italy|IRCCS San Donato, Milan, Italy|IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 500
  • Age - 18 Years to 85 Years   (Adult, Older Adult)
  • Outcome measures - Cardiovascular mortality|All-cause mortality|Major adverse cardiovascular events (myocardial infarction, cerebrovascular accident, hospitalizations due to heart failure, revascularizations, cardiovascular mortality)|NYHA class|Left ventricular systolic function (cardiac magnetic resonance, echocardiography)
NCT04361877 Cardiovascular Prevention During COVID-19 Pandemic Lockdown in Young Adults (COLA Trial) Completed Mar/30/2020 Apr/20/2020
  • Alternative id - 20-268 KB
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - University Hospital Munich (LMU Klinikum), Munich, Germany
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 1900
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Change of physical activity|change of nutrition behaviour|semiquantitative change of alcohol intake|change of smoking behaviour|change of stress level|step count
NCT05080192 Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate Recruiting Feb/26/2021 Dec/31/2022
  • Alternative id - 844349
  • Interventions - Drug: Fenofibrate|Drug: Placebo
  • Study type - Observational
  • Study results - No Results Available
  • Locations - University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Study designs - Observational Model: Case-Control|Time Perspective: Prospective
  • Enrollment - 40
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Flow Mediated dilation of the brachial artery|Arterial wave reflection magnitude|Large Artery Stiffness|Myocardial function|Diffusion capacity of lungs for carbon monoxide (DLCO)|Aerobic capacity|Quality of life
NCT04636021 Restoring Non-Emergent Cardiovascular Care in the Peri- COVID-19 Era Recruiting Aug/01/2020 Jun/30/2022
  • Alternative id - UPMCP # 20-007
  • Interventions - Diagnostic Test: COVID-19 testing
  • Study type - Observational
  • Study results - No Results Available
  • Locations - UPMC Pinnacle Harrisburg, Harrisburg, Pennsylvania, United States
  • Study designs - Observational Model: Other|Time Perspective: Prospective
  • Enrollment - 1000
  • Age - Child, Adult, Older Adult
  • Outcome measures - Number of subjects who contract COVID-19 while hospitalized for elective outpatient procedures|Patient perception of the effect of pre and post procedure COVID-19 testing on risk of contracting COVID-19 while hospitalized for an elective outpatient procedure.
NCT04379453 Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses Recruiting Not Applicable Apr/27/2020 Apr/27/2020
  • Alternative id - 4094-20
  • Interventions - Procedure: Robot Assisted Percutaneous Cardiovascular Intervention
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital Israelita Albert Einstein, São Paulo, Brazil
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 10
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Successful cardiovascular intervention|Performed with the professional team positioned at> 2 meters from the patient for at least 50% of the duration of the intervention|absence of fatal complications caused by the procedure or acute non-fatal vessel occlusion during index admission
NCT04505098 A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults Active, not recruiting Phase 4 Aug/07/2020 Feb/28/2023
  • Alternative id - 1597940
  • Interventions - Drug: Icosapent ethyl
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Kaiser Permanente Northern California, Oakland, California, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 39600
  • Age - 50 Years and older   (Adult, Older Adult)
  • Outcome measures - Rate of confirmed viral URIs|Percentage of patients with moderate or severe confirmed viral URIs|Worst clinical status due to a confirmed viral URI
NCT04354610 Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection Completed Not Applicable Apr/27/2020 Mar/26/2021
  • Alternative id - 2020PI072
  • Interventions - Procedure: Biological samples specific to research|Procedure: Clinical examination|Procedure: Telephone follow-up
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - CHRU de Nancy, Nancy, France|CHRU de Nancy, Vandœuvre-lès-Nancy, France
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other
  • Enrollment - 73
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Worsening of renal function by at least KDIGO grade 1 during hospitalization for Covid-19 infection|Troponin greater than 99th percentile during hospitalization for Covid-19 infection|AKI KDIGO grade 1 or higher in hospitalisation (approach with AND without a priori)|Elevation of troponin> 99th percentile in hospitalisation (approach with AND without a priori)|AKI KDIGO grade 1 or higher|Association with troponin elevation >99th|Association with elevation of serum creatinine >30%|With the onset of chronic renal failure (eDFG <60 ml / min / 1.73m2)|The occurrence of cardiovascular events (stroke, myocardial infarction, hospitalisation for heart failure, cardiovascular death) during hospitalisation and three months after discharge from hospital|The occurrence of death from any cause during hospitalisation and three months after discharge from hospital
NCT04811885 The Effects of Covid-19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder Active, not recruiting Oct/14/2019 Oct/14/2021
  • Alternative id - Institute Technology Carlow
  • Interventions - Other: The Effects of Covid 19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Institute of Technology Carlow, Carlow, Lenister, Ireland
  • Study designs - Observational Model: Cohort|Time Perspective: Cross-Sectional
  • Enrollment - 120
  • Age - 4 Years to 18 Years   (Child, Adult)
  • Outcome measures - The Effects of Covid-9 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder
NCT04615949 Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors Recruiting Phase 2|Phase 3 Apr/30/2021 Apr/01/2022
  • Alternative id - CARDIOL 100-03
  • Interventions - Drug: Cannabidiol, pharmaceutically produced with < 5 ppm THC|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Valleywise Health Medical Center, Phoenix, Arizona, United States|Westchester General Hospital, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Prairie Education and Research Cooperative, Springfield, Illinois, United States|Lutheran Health Physicians, Fort Wayne, Indiana, United States|Lowcountry Infectious Disease, Charleston, South Carolina, United States|PRX Research/Dallas Regional Medical Center, Mesquite, Texas, United States|University of Texas Health Science Center, San Antonio, Texas, United States|Baylor Scott & White Health - Temple, Temple, Texas, United States|Liga de Hipertensão arterial, Goiânia, Goiás, Brazil|Sociedade Hospitalar Angelina Caron, Campina Grande Do Sul, Parana, Brazil|Science Valley Research Institute, Campo Largo, Parana, Brazil|Universidade Estadual de Maringa, Maringa, Parana, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital São Lucas PUCRS, Porto Alegre, Rio Grande Do Sul, Brazil|Irmandade Santa Casa de Misericórdia, Porto Alegre, Rio Grande Do Sul, Brazil|Núcleo de Ensino e Pesquisa do Instituto Mário Penna, Conjunto ACM, Santa Maria, Brazil|Fundação Pio XII - Hospital de Amor Barretos, Barretos, Sao Paulo, Brazil|Science Valley Research Institute- Hospital Municipal de Barueri Dr. Francisco Moran, Barueri, Sao Paulo, Brazil|IPECC-Instituto de Pesquisa Clínica de Campinas, Campinas, Sao Paulo, Brazil|Instituto do Coração do HCFMUSP, Cerqueira César, Sao Paulo, Brazil|SVRI- Irmandade de Santa Casa de Misercordia de Santos, Jabaquara, Sao Paulo, Brazil|Science Valley Research Institute, Morumbi, Sao Paulo, Brazil|Science Valley Research Institute, Santo André, Sao Paulo, Brazil|Fundação Faculdade Regional de Medicine de Sao Jose do Rio Preto (SJRP), São José Do Rio Preto, Sao Paulo, Brazil|IAMSPE - Instituto de Assitencia Medica do Servidor Público Estadual, São Paulo, Sao Paulo, Brazil|Hospital 9 de Julho, São Paulo, Sao Paulo, Brazil|Hucff- Ufrj, Rio De Janeiro, Brazil|Complexo Hospitalar de Niteroi- Centro de Pesquisa Clinica, Rio de Janeiro, Brazil|Charite Universitatsmedizin Berlin, Berlin, Germany|Medical School of Bradenburg Theodor Fontane (MHB), Neuruppin, Germany|TecSalud, Monterrey, Nuevo Leon, Mexico|Unidad Medica para la Salud Integral UMSI, San Nicolás De Los Garza, Nuevo Leon, Mexico|Centro para el Desarrollo de la Medicina Y de la Asistencia Medica Especializada, Culiacan, Sinaloa, Mexico
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 422
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - All-cause mortality|Requirement for ICU admission and/or ventilatory support|CV complications
NCT04921241 In Utero Exposure to SARS-CoV-2 (COVID-19) and Cardiovascular and Metabolic Endpoints in Early Life Enrolling by invitation Jun/08/2021 Jun/07/2023
  • Alternative id - 2021P001107
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Massachusetts General Hospital, Boston, Massachusetts, United States
  • Study designs - Observational Model: Cohort|Time Perspective: Cross-Sectional
  • Enrollment - 240
  • Age - 9 Months and older   (Child, Adult, Older Adult)
  • Outcome measures - Aortic pulse-wave velocity|Skinfold thicknesses (subscapular, triceps)|Weight-for-length z-score|Systolic and diastolic blood pressure|Beta index of aortic stiffness using echocardiogram|Aortic intima-media thickness using echocardiogram|Urinary angiotensin peptide levels|Urinary angiotensin converting enzyme (ACE) levels
NCT04452630 Cardiovascular Consequences After COVID-19 Recruiting Jun/23/2020 Nov/30/2021
  • Alternative id - 2020-36
  • Interventions - Other: Infectious Disease and Cardiology Clinical Consultations
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Assistance Publique Hôpitaux de Marseille, Marseille, France
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 200
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Presence of at least one clinical, biological and/or imaging cardiovascular anomaly within 1 month of recovering
NCT04365699 Cardiovascular Effects of COVID-19 Completed Phase 2 Apr/08/2020 Jan/31/2021
  • Alternative id - 20-00416
  • Interventions - Drug: AT-001
  • Study type - Interventional
  • Study results - Has Results
  • Locations - NYU Langone Health, New York, New York, United States
  • Study designs - Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 81
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Hospital Length of Stay (LOS)|Percentage of Participants Who Died
NCT04701515 Cardiovascular Manifestations of COVID-19 Recruiting Jun/10/2020 Dec/31/2022
  • Alternative id - 030.CVS.2020.D
  • Interventions - Other: Chart review
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Methodist Dallas Medical Center, Dallas, Texas, United States
  • Study designs - Observational Model: Cohort|Time Perspective: Other
  • Enrollment - 500
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Heart failure|Tamponade|Pericardial Effusion|Myocarditis|Pericarditis|Arrythmias|Troponin I|N-terminal prohormone BNP|Stroke|Myocardial infarction|Shock|Deep venous thrombosis|Discharge disposition|Primary diagnosis|Rate of ICU admission/transfer|Total hospital length of stay|ICU length of stay|Percentage of patients in cohort that had EKG testing or Echocardiography
NCT04661657 COvid-19 LongitUdinal Multiethnic BioImaging Assessment of CARDiovascular Sequelae Registry Recruiting Dec/28/2020 Sep/30/2022
  • Alternative id - AAAT0787
  • Interventions - Other: Transthoracic echocardiogram (TTE)|Other: Cardiovascular Magnetic Resonance (CMR) Imaging
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Columbia University Irving Medical Center, New York, New York, United States
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 70
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Percentage of myocardium demonstrating late gadolinium enhancement|Extracellular Volume (ECV) Fraction|Left Ventricular Ejection Fraction
NCT04508920 A Survey to Assess Effects of Covid-19 on Cardiovascular Patients Recruiting May/15/2019 Jul/15/2021
  • Alternative id - 20-1156
  • Interventions - Other: Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA)
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Centro de Insuficiencia Cardiaca Instituto Nacional de Cardiologia, Mexico City, Mexico
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 76
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - NYHA class deterioration|Dyspnea deterioration|Paroxysmal nocturnal dyspnea deterioration|Edema|Daily activities In the last four weeks? Please, mention if you a perceived limitation on : Walking deterioration
NCT04983823 Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE) Recruiting Not Applicable Nov/18/2021 Dec/01/2024
  • Alternative id - 28/21
  • Interventions - Other: Heart Failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)|Other: Usual care
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening
  • Enrollment - 820
  • Age - 50 Years to 85 Years   (Adult, Older Adult)
  • Outcome measures - New onset heart failure|Change in exercise capacity|Change in maximal isometric grip strength|Change on quality of life
NCT04327479 Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection Active, not recruiting Mar/26/2020 Mar/25/2026
  • Alternative id - 20-9213-BO
  • Interventions - Diagnostic Test: Assessment of cardiovascular diseases and cardiovascular risk factors
  • Study type - Observational
  • Study results - No Results Available
  • Locations - University Hospital Essen, Essen, NRW, Germany
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 728
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - All-cause mortality|30-day mortality|Major adverse cardiovascular events
NCT04984564 Cardiovascular Fellow-in-training Feedback on Virtual and Simulator-based Learning Experience in A Low to Middle Income Country Completed Jul/01/2020 Aug/31/2020
  • Alternative id - 2020-5030-10817
  • Interventions - Other: None. As this was an observational study.
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Pirbhat Shams, Karachi, Outside US And Canada, Pakistan
  • Study designs - Observational Model: Other|Time Perspective: Cross-Sectional
  • Enrollment - 68
  • Age - Child, Adult, Older Adult
  • Outcome measures - Feedback of individual fellow in training on virtual and simulator based learning.
NCT05077943 The Effect of Home-based Exercise on Functional Capacity of Covid-19 Survivor With Cardiovascular Comorbidity Recruiting Not Applicable Sep/01/2021 Nov/30/2022
  • Alternative id - Home based Exercise PostCovid
  • Interventions - Behavioral: Breathing and chest mobilization exercises|Behavioral: Second phase cardiac rehabilitation
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - National Cardiovascular Center Harapan Kita Hospital Indonesia, Jakarta, Indonesia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  • Enrollment - 66
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Change of Peak Cough Flow (PC)|Change of Peak Flow Rate (PFR)|Change of Cardiac Exercise Test|Change of 6-minutes walking test|Change of Hemoglobin|Change of Hematocrit|Change of Erythrocyte|Change of Mean Corpuscular Volume|Change of Mean Corpuscular Hemoglobin|Change of Mean Corpuscular Hemoglobin Concentration|Change of Red Cell Distribution Width|Change of Leucocyte|Change of Platelet|Change of European Quality of Life Five Dimension (EQ-5D)|Change of Basophil|Change of Eosinophil|Change of Neutrophil|Change of Lymphocyte|Change of Monocyte|Change of C-Reactive Protein|Change of D-dimer
NCT04368637 Acute Cardiovascular Events Triggered by COVID-19-Related Stress Recruiting May/03/2020 Aug/30/2020
  • Alternative id - JCCG.JoCORE.4.4040
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Istishari Hospital, Amman, Jordan|Abdelhadi Hospital, Amman, Jordan|Farah Hospital, Amman, Jordan|Jordan Hospital, Amman, Jordan|Specialty Hospital, Amman, Jordan
  • Study designs - Observational Model: Cohort|Time Perspective: Cross-Sectional
  • Enrollment - 50
  • Age - 18 Years to 100 Years   (Adult, Older Adult)
  • Outcome measures - Acute cardiovascular event triggered by COVID-19 stress|Ventricular tachycardia|acute stroke|Implantable cardioverter defibrillator (ICD) shock
NCT04864899 Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance (R-COVID-CMR) Recruiting Not Applicable Sep/01/2021 Dec/31/2023
  • Alternative id - UW21-005
  • Interventions - Diagnostic Test: Cardiac Magnetic Resonance Imaging (CMR)|Diagnostic Test: Blood test|Diagnostic Test: 6-minute walk test
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - The University of Hong Kong, Hong Kong, Hong Kong
  • Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic
  • Enrollment - 112
  • Age - Child, Adult, Older Adult
  • Outcome measures - The extent of myocardial involvement, as assessed by CMR tissue characterisation (T1/ T2/ ECV/ LGE), change from 2 weeks after patient recovery, at 3-months post discharge and at 1-year post discharge.|The correlation of these myocardial characteristics to biventricular structure at all time-points.|The correlation of these myocardial characteristics to biventricular function (CMR cine/strain) at all time-points.|The correlation of these myocardial characteristics to blood biomarkers of inflammation at all time-points.|The correlation of these myocardial characteristics to clinical symptoms at all time-points.|The correlation of these myocardial characteristics to functional capacity (6 minute walk test) at all time-points.|Follow-up patients beyond the end of this study to assess for hard outcomes such as death.|Follow-up patients beyond the end of this study to assess for hard outcomes such as heart failure hospitalisation.|Follow-up patients beyond the end of this study to assess for hard outcomes such as cardiac arrest.|Follow-up patients beyond the end of this study to assess for hard outcomes such as ventricular tachycardia/ fibrillation.
NCT04658433 The Effect of Omega -3 Supplements on the Serum Levels of ACE/ACE2 Ratio as a Potential Key in Cardiovascular Disease and COVID-19; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People Completed Not Applicable Mar/05/2021 Feb/10/2022
  • Alternative id - 2020-PHA-22
  • Interventions - Dietary Supplement: 300 mg of omega3-FA
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Mahmoud S Abu-Samak, Amman, Jordan
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention
  • Enrollment - 100
  • Age - 35 Years to 65 Years   (Adult, Older Adult)
  • Outcome measures - serum ACE levels|serum ACE2 levels|Lipid profile mg/dL
NCT04661189 The Cognitive and spOrt Virtual EPIC Training Study for Cardiovascular Diseases Recruiting Not Applicable May/18/2020 Dec/01/2022
  • Alternative id - ICM 2020-2785
  • Interventions - Behavioral: Physical exercise training|Behavioral: Cognitive training
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Preventive medicine and physical activity centre (centre EPIC), Montreal Heart Institute, Montréal, Quebec, Canada
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 122
  • Age - 50 Years to 100 Years   (Adult, Older Adult)
  • Outcome measures - Change in general cognitive functioning|Change in executive functions|Change in processing speed|Change in episodic memory|Change in Walking speed|Change in Functional mobility|Change in Balance performance|Change in Lower limb muscles strength|Change in Cardiorespiratory fitness
NCT05033613 Home Blood Pressure Monitoring Before and After COVID-19 Vaccination in Patients at High Risk of Cardiovascular Disease Recruiting Sep/10/2021 Dec/29/2022
  • Alternative id - 202107076RINA
  • Interventions - Other: heart rate、arrhythmia、blood pressure、central body temperature (ear temperature) and blood oxygen saturation level.
  • Study type - Observational
  • Study results - No Results Available
  • Locations - National Taiwan University Hospital, Taipei, Chung-Shan, Taiwan
  • Study designs - Observational Model: Case-Only|Time Perspective: Prospective
  • Enrollment - 1500
  • Age - 20 Years to 90 Years   (Adult, Older Adult)
  • Outcome measures - Compare the physiological effects of different type of COVID-19 vaccines|Compare whether the subjective side effects of different type of COVID-19 vaccines are different|Compare the psychological stress effects of different type of COVID-19 vaccines
NCT04397835 Psychological Impact of COVID-19 Quarantine and Worsening of Cardiovascular Risk in the French General Population Recruiting Apr/17/2020 Apr/20/2021
  • Alternative id - RC31/20/0135
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - CHU de Toulouse, Toulouse, Occitanie, France
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 800
  • Age - 50 Years to 89 Years   (Adult, Older Adult)
  • Outcome measures - worsening of cardiovascular risk (treatments)|worsening of cardiovascular risk (smoking consumption)|worsening of cardiovascular risk (food balance)|worsening of cardiovascular risk (weight gain)|worsening of cardiovascular risk (physical activity)|psychological impact of the quarantine on anxiety|psychological impact of the quarantine on health|psychological impact of the quarantine on stress
NCT02344290 Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults Active, not recruiting Phase 3 Mar/26/2015 Mar/26/2023
  • Alternative id - A5332|11960|1U01HL123339-01|1U01HL123336-01|EU5332
  • Interventions - Drug: Pitavastatin|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Alabama CRS, Birmingham, Alabama, United States|University of Arizona CRS, Tucson, Arizona, United States|University of Southern California CRS, Los Angeles, California, United States|UCLA CARE Center CRS, Los Angeles, California, United States|Mills Clinical Research CRS, Los Angeles, California, United States|VA West Los Angeles Medical Center CRS, Los Angeles, California, United States|Los Angeles LGBT Center CRS, Los Angeles, California, United States|Eisenhower Health Center at Rimrock CRS, Palm Springs, California, United States|Stanford AIDS Clinical Trials Unit CRS, Palo Alto, California, United States|UCSD Antiviral Research Center CRS, San Diego, California, United States|Ucsf Hiv/Aids Crs, San Francisco, California, United States|Harbor-UCLA CRS, Torrance, California, United States|University of Colorado Hospital CRS, Aurora, Colorado, United States|Denver Public Health CRS, Denver, Colorado, United States|Yale University CRS, New Haven, Connecticut, United States|VA Connecticut Healthcare System CRS, West Haven, Connecticut, United States|Whitman-Walker Health CRS, Washington, District of Columbia, United States|Georgetown University CRS (GU CRS), Washington, District of Columbia, United States|Capital Medical Associates, PC CRS, Washington, District of Columbia, United States|Infectious Diseases Clinic, Washington DC Veterans Affairs Medical Center CRS, Washington, District of Columbia, United States|Malcom Randall VA Medical Center CRS, Gainesville, Florida, United States|AHF-The Kinder Medical Group CRS, Miami, Florida, United States|The University of Miami AIDS Clinical Research Unit (ACRU) CRS, Miami, Florida, United States|University of Miami Infectious Disease Research Unit at Jackson Memorial Hospital CRS, Miami, Florida, United States|AHF - South Beach CRS, Miami, Florida, United States|Orlando Immunology Center CRS, Orlando, Florida, United States|Community AIDS Network/Comprehensive Care Clinic CRS, Sarasota, Florida, United States|Florida Department of Health - Hillsborough County, Tampa, Florida, United States|AIDS Research and Treatment Center of the Treasure Coast CRS, Vero Beach, Florida, United States|The Ponce de Leon Center CRS, Atlanta, Georgia, United States|Augusta University Research Institute, Inc. CRS, Augusta, Georgia, United States|Northwestern University CRS, Chicago, Illinois, United States|Rush University CRS, Chicago, Illinois, United States|UIC Project WISH CRS, Chicago, Illinois, United States|Indiana University Infectious Diseases Research CRS, Indianapolis, Indiana, United States|Department of Internal Medicine, University of Iowa Hospitals & Clinics CRS, Iowa City, Iowa, United States|Bluegrass Care Clinic/University of Kentucky Research Foundation CRS, Lexington, Kentucky, United States|550 Clinic -University of Louisville CRS, Louisville, Kentucky, United States|Tulane - Louisiana Community AIDS Research Program (T-LaCARP) CRS, New Orleans, Louisiana, United States|Johns Hopkins University CRS, Baltimore, Maryland, United States|Tufts Medical Center CRS, Boston, Massachusetts, United States|Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States|Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS, Boston, Massachusetts, United States|Boston Medical Center CRS, Boston, Massachusetts, United States|Baystate Infectious Diseases Clinical Research CRS, Springfield, Massachusetts, United States|Henry Ford Hosp. CRS, Detroit, Michigan, United States|St. John Newland Medical Associates CRS, Southfield, Michigan, United States|Abbott Northwestern Hospital CRS, Minneapolis, Minnesota, United States|University of Mississippi Medical Center CRS, Jackson, Mississippi, United States|Washington University Therapeutics (WT) CRS, Saint Louis, Missouri, United States|Specialty Care Center CRS, Omaha, Nebraska, United States|Cooper Univ. Hosp. CRS, Camden, New Jersey, United States|New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States|James J Peters VA Medical Center CRS, Bronx, New York, United States|Mount Sinai Beth Israel CRS, New York, New York, United States|VA New York Harbor Healthcare System (NYHHS), NY Campus CRS, New York, New York, United States|Weill Cornell Chelsea CRS, New York, New York, United States|Mount Sinai Downtown CRS, New York, New York, United States|Mount Sinai West Samuels CRS, New York, New York, United States|Mount Sinai St. Luke's Morningside CRS, New York, New York, United States|Infectious Disease Clinical and Translational Research Center (CTRC) CRS, New York, New York, United States|Columbia P&S CRS, New York, New York, United States|Weill Cornell Uptown CRS, New York, New York, United States|University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester, New York, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Duke University Medical Center CRS, Durham, North Carolina, United States|Greensboro CRS, Greensboro, North Carolina, United States|Wake Forest Baptist Medical Center CRS, Winston-Salem, North Carolina, United States|Cincinnati Clinical Research Site, Cincinnati, Ohio, United States|Case Clinical Research Site, Cleveland, Ohio, United States|Ohio State University CRS, Columbus, Ohio, United States|University of Toledo Medical Center CRS, Toledo, Ohio, United States|Oklahoma State University Center for Health Sciences CRS, Tulsa, Oklahoma, United States|Division of Infectious Diseases Clinical Research Center- Drexel University CRS, Philadelphia, Pennsylvania, United States|Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States|Center of Translational AIDS Research, Lewis Katz School of Medicine at Temple University CRS, Philadelphia, Pennsylvania, United States|Positive Health Clinic CRS, Pittsburgh, Pennsylvania, United States|University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States|The Miriam Hospital Clinical Research Site (TMH CRS) CRS, Providence, Rhode Island, United States|Medical University of South Carolina: Division of Infectious Diseases CRS, Charleston, South Carolina, United States|Palmetto Health Clinical Trial Department CRS, Columbia, South Carolina, United States|Vanderbilt Therapeutics (VT) CRS, Nashville, Tennessee, United States|Trinity Health and Wellness Center CRS, Dallas, Texas, United States|Dallas VA Medical Center CRS, Dallas, Texas, United States|UT Southwestern HIV/ID Clinical Trials Unit CRS, Dallas, Texas, United States|Houston AIDS Research Team CRS, Houston, Texas, United States|Michael E. DeBakey VAMC REPRIEVE CRS, Houston, Texas, United States|Inova Heart and Vascular Institute CRS, Falls Church, Virginia, United States|Virginia Commonwealth University CRS, Richmond, Virginia, United States|University of Washington AIDS CRS, Seattle, Washington, United States|Medical College of Wisconsin, Inc. CRS, Milwaukee, Wisconsin, United States|Gaborone CRS, Gaborone, South-East District, Botswana|Tropical Medicine Foundation Dr. Heitor Vieira Dourado CRS, Manaus, Amazonas, Brazil|School of Medicine, Federal University of Minas Gerais CRS, Belo Horizonte, Minas Gerais, Brazil|HGNI HIV Family Care Clinic - HHFCC CRS, Nova Iguacu, Rio De Janeiro, Brazil|Hospital Nossa Senhora da Conceicao CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Centro de Referencia e Treinamento DST/AIDS CRS, Sao Paulo, São Paulo, Brazil|Projeto Praça Onze Pesquisa em Saúde CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado CRS, Rio de Janeiro, Brazil|Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio de Janeiro, Brazil|Instituto de Infectologia Emilio Ribas CRS, Sao Paulo, Brazil|Centro de Pesquisas Clínicas IC-HCFMUSP CRS, Sao Paulo, Brazil|Vancouver ID Research & Care Centre Society CRS, Vancouver, British Columbia, Canada|Hamilton Health Sciences - Special Immunology Services Clinic CRS, Hamilton, Ontario, Canada|Maple Leaf Research CRS, Toronto, Ontario, Canada|Toronto General Hospital CRS, Toronto, Ontario, Canada|Chronic Viral Illness Service CRS, Montreal, Quebec, Canada|Centre hospitalier de l'Université Laval CRS, Quebec City, Quebec, Canada|GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS, Port-au-Prince, Haiti|Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince, Haiti|Byramjee Jeejeebhoy Medical College (BJMC) CRS, Pune, Maharashtra, India|Chennai Antiviral Research and Treatment (CART) CRS, Chennai, Tamil Nadu, India|Barranco CRS, Lima, Peru|San Miguel CRS, Lima, Peru|Puerto Rico AIDS Clinical Trials Unit CRS, San Juan, Puerto Rico|Soweto ACTG CRS, Johannesburg, Gauteng, South Africa|Wits Helen Joseph Hospital CRS (Wits HJH CRS), Johannesburg, Gauteng, South Africa|Durban International Clinical Research Site CRS, Durban, Kwa Zulu Natal, South Africa|University of Cape Town Lung Institute (UCTLI) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Universitario Valle d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario de Bellvitge, Barcelona, Spain|Hospital Universitario de Basurto de Basurto, Bilbao, Spain|Hospital General Universitario De Elche, Elche, Spain|Hospital Gregorio Universitario Maranon, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Thai Red Cross AIDS Research Centre (TRC-ARC) CRS, Bangkok, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Joint Clinical Research Centre (JCRC)/Kampala Clinical Research Site, Kampala, Uganda|Milton Park CRS, Harare, Zimbabwe
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 7770
  • Age - 40 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - Time to the first event of a composite of major cardiovascular events|Time to the first of each individual component of the primary endpoint|Time to death (all-cause mortality)|Time to death (all-cause mortality) and/or major adverse cardiovascular events (MACE)|Time to any (composite) or each (individual) of the following clinical diagnoses (including recurrent diagnoses as appropriate)|Calculated fasting low-density lipoprotein (LDL) and non-high-density lipoprotein (HDL) cholesterol level|Time to any of the following adverse events (including recurrent events as appropriate)|Incidence of COVID-19|Incidence of serious COVID-19|For substudy: volume of NCP at study entry and change in NCP over 2 years|For substudy: evidence of non-calcified coronary atherosclerotic plaque (NCP)|For substudy: progression of NCP|For substudy: number of high risk plaque features|For substudy: changes in inflammatory markers
NCT04879251 The Impact of the COVID-19 Pandemic on Cardiovascular Risk Factors in Patients With Diabetes Recruiting Apr/26/2021 Aug/31/2022
  • Alternative id - 3/IK-FNO/2021
  • Interventions - Other: No intervention
  • Study type - Observational
  • Study results - No Results Available
  • Locations - University Hospital Ostrava, Ostrava, Czechia
  • Study designs - Observational Model: Cohort|Time Perspective: Other
  • Enrollment - 1000
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of patients with diabetes who have a worse glycated hemoglobin value (Change from baseline after 1 and 2 year of COVID 19 pandemic)|Number of patients with diabetes who have a worse LDL cholesterol value (Change from baseline after 1 and 2 year of COVID 19 pandemic)|Number of patients with diabetes who have a higher BMI value (Change from baseline after 1 and 2 year of COVID 19 pandemic)|Number of patients with diabetes who have a higher BP (blood pressure) value (Change from baseline after 1 and 2 year of COVID 19 pandemic)
NCT04335630 Cardiovascular Manifestations of COVID-19 Recruiting Mar/30/2020 Mar/01/2022
  • Alternative id - HSC-MS-20-0286
  • Interventions - Diagnostic Test: Electrocardiogram, telemetry, echocardiogram, laboratory values
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Memorial Hermann Hospital-Texas Medical Center, Houston, Texas, United States
  • Study designs - Observational Model: Case-Control|Time Perspective: Retrospective
  • Enrollment - 500
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Prevalence of cardiomyopathy, myocardial infarction, heart failure, clinically significant arrhythmias, cardiogenic shock or cardiac arrest.|Prevalence of pericarditis, pericardial effusion, valvular disease.|Identification of characteristic electrocardiographic patterns related to COVID-19|Role of active cardiovascular disease in clinical outcomes of patients with COVID-19 including length of ICU stay, length of hospitalization and mortality.|Role of pre-existing cardiovascular comorbidities in clinical course of COVID-19|Role of treatment with ACE inhibitors or ARBs in the clinical course of COVID-19|Role of insurance type on clinical outcomes of patients with COVID-19|Effect of age, gender and race on clinical course of COVID-19 and prevalence of cardiovascular complications|Role of active smoking on clinical course of COVID-19 and prevalence of cardiovascular complications
NCT04335162 Cardiovascular Complications and COVID-19 (CovCardioVasc-Study) Recruiting Feb/28/2020 Aug/31/2021
  • Alternative id - 20reamedcovid01
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Centre Hospitalier de Cannes, Cannes, France|CHU de Dijon, Dijon, France|Centre Hospitalier de Draguignan, Draguignan, France|Centre Hospitalier de Grasse, Grasse, France|Clinique Ambroise-Paré, Neuilly, France|CHU de Nice, Nice, France|Hôpitaux Universitaires Paris Centre - Hôpital Cochin, Paris, France|CHU de REIMS, Reims, France
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 100
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Determine the incidence of cardiomyopathies and venous thromboembolism|Mortality|Duration of mechanical ventilation|Shock|length of stay|Mechanical ventilation|Renal replacement therapy
NCT04498091 EPIdemiological Approaches to the Cardiovascular Consequences of COVID-19 Active, not recruiting Mar/15/2020 Jul/01/2021
  • Alternative id - Zeller AOIc 2020
  • Interventions - Biological: Biological data|Other: Clinical data
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Chu Dijon Bourgogne, Dijon, France
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 35
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Characterizing type 2 myocardial infarction associated with CoV-2 SARS infection
NCT05092711 Cardiovascular Risk Factors , Complications and Threputic Management Strategies in Patients With Coronary Heart Disease and COVID 19 Not yet recruiting Nov/01/2021 Mar/01/2023
  • Alternative id - COVIHD
  • Interventions - Behavioral: Observation|Drug: Observation
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Assuit university, Assiut, Egypt
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 150
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - • To determine in patients with established CHD (acute myocardial infarction and ischaemia and patients following revascularisation by angioplasty or coronary artery surgery) whether the guidelines on cardiovascular disease prevention are being followed.|• To follow-up all patients one year after the interview for hospitalisations, cardiovascular procedures, cardiovascular events and cardiovascular and all cause mortality|• To describe the prevalence of cardiovascular risk factors, acute and long-term cardiovascular complications and therapeutic management in patients with CHD and COVID-19|• To compare the risk factor profiles in CHD patients with and without a history of COVID-19|• To compare the diagnostic and therapeutic strategies in CHD patients with and without a history of COVID-19|• To compare the acute and long-term cardiovascular complications in CHD patients with and without a history of COVID-19|• To compare diagnostic and therapeutic strategies in prevalent cases of familial hypercholesterolaemia in patients with established coronary disease and the residual risk among these patients with current treatments.|• To compare diagnostic and therapeutic strategies in patients with established coronary disease in relation to glucose metabolism (impaired fasting glycaemia, impaired glucose tolerance and diabetes).
NCT05021575 Effects of COVID-19 Pandemic on a Health Care System: Case Study of the CirculatORy System in LiThuania Completed Jun/01/2020 Dec/31/2020
  • Alternative id - S-COV-20-27|2020/8-1247-730
  • Interventions - Other: Data collection on outpatient care|Other: Data collection on hospitalisation|Other: Data collection on cardiovascular mortality|Other: Data collection of patients presenting to the tertiary care centre with acute coronary syndrome
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Institute of Hygiene, Vilnius, Lithuania|National Health Insurance Fund under the Ministry of Health, Lithuania, Vilnius, Lithuania|Vilnius University, Vilnius, Lithuania
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 839678
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of outpatient care visits for cardiovascular reasons in Lithuania in 2019 and 2020|Number of cardiovascular hospitalisations in Lithuania in 2019 and 2020|Cardiovascular mortality rates in Lithuania in 2019 and 2020|Evaluation of sex and age differences in changes of CV care provision and CV deaths during the pandemic and comparison between 2019 and 2020|In-hospital mortality rates in Lithuania in 2019 and 2020|Comparison of distribution of death places in Lithuania in 2019 and 2020|Comparison of all-cause mortality during the hospital stay and at 3 months of follow-up in patients presenting to a tertiary care centre with acute coronary syndrome during the first quarantine in 2020 and in a corresponding period of 2019
NCT04475471 WORLD HEART FEDERATION (WHF) COVID-19 and Cardiovascular Disease Survey Recruiting Jun/11/2020 Dec/30/2021
  • Alternative id - RA1413
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Hospital de Clinicas of the University, Buenos Aires, Argentina|Hospital de Clinicas of the University, Buenos Aires, Argentina|Hospital de Clinicas of the University, Buenos Aires, Argentina|Hospital de Clinicas of the University, Buenos Aires, Argentina|Hospital de Clinicas of the University, Buenos Aires, Argentina|Sanatorio Güemes Hospital, Buenos Aires, Argentina|University Clinical Center Republic of Srpska, Srpska, Bosnia and Herzegovina|Komfo Anokye Teaching Hospital, Kumasi, Ghana|Kumasi South Regional Hospital, Kumasi, Ghana|Dayanand medical college hospital, Ludhiyana, Punjab, India|Amin Hospital, Isfahan, Iran, Islamic Republic of|Amin Hospital, Isfahan, Iran, Islamic Republic of|Khorshid Hospital, Isfahan, Iran, Islamic Republic of|Fedail Hospital, Khartoum, Sudan
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 5200
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Assessment of the patients for major adverse cardiovascular events (MACE)|Assessment of the patients for Pulmonary outcomes including Pulmonary embolism, pneumonia, acute respiratory distress syndrome, need of intensive care - number of days in ICU or ICCU, need of ventilator]|Assessment of the patients for Neurological Outcomes including stroke and Transient Ischemic Attack (TIA)|All cause deaths
NCT04392089 Effects of Cardiovascular and Pulmonary Optimization on Cerebral Oxygenation in COVID-19 Patients With Severe ARDS Recruiting May/01/2020 May/01/2021
  • Alternative id - H-20027818
  • Interventions - Device: Masimo, LidCO
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Hvidovre Hospital, Copenhagen, Denmark
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 20
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Changes in cerebral oxygenation (ScO2) during cardiovascular and pulmonary optimization|Changes in peripheral oxygen saturation (SatO2) during cardiovascular and pulmonary optimization|Changes in systolic arterial pressure (SAP) during cardiovascular and pulmonary optimization|Changes in diastolic arterial pressure (DAP) during cardiovascular and pulmonary optimization|Changes in mean arterial pressure (MAP) during cardiovascular and pulmonary optimization|Changes in heart rate (HR) during cardiovascular and pulmonary optimization|Changes in stroke volume (SV) during cardiovascular and pulmonary optimization|Changes in cardiac output (CO) during cardiovascular and pulmonary optimization|Changes in systemic vascular resistance (SVR) during cardiovascular and pulmonary optimization|Changes in peripheral perfussion index (PPI) during cardiovascular and pulmonary optimization|Changes in pH during cardiovascular and pulmonary optimization|Changes in PaO2 during cardiovascular and pulmonary optimization|Changes in PaCO2 during cardiovascular and pulmonary optimization|Changes in arterial saturation (SaO2) during cardiovascular and pulmonary optimization|Changes in PvO2 during cardiovascular and pulmonary optimization|Changes in PvCO2 during cardiovascular and pulmonary optimization|Changes in mixed venous saturation (SvO2) during cardiovascular and pulmonary optimization|Changes in lacatate during cardiovascular and pulmonary optimization|Changes in hemoglobine concentration (Hb) during cardiovascular and pulmonary optimization|Changes in muscular oxygenation (SmO2) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and peripheral oxygen saturation (SatO2) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and systemic arterial pressure (SAP) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and diastolic arterial pressure (DAP) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and mean arterial pressure (MAP) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and stroke volume (SV) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and heart rate (HR) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and cardiac output (CO) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and systemic vascular resistance (SVR) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and peripheral perfussion index (PPI) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and pH during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and PaO2 during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and PaCO2 during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and arterial saturation (SaO2) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and PvO2 during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and PvCO2 during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and mixed venous saturation (SvO2) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and lactate during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and hemoglobine concentration (Hb) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and muscular oxygenation (SmO2) during cardiovascular and pulmonary optimization
NCT04605965 WEAICOR: Wearables to Investigate the Long Term Cardiovascular and Behavioral Impacts of COVID-19 Active, not recruiting Jun/09/2020 Nov/01/2023
  • Alternative id - 2020-678
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Tulane University, TRIAD Center, New Orleans, Louisiana, United States|Tulane University, New Orleans, Louisiana, United States
  • Study designs - Observational Model: Case-Only|Time Perspective: Prospective
  • Enrollment - 200
  • Age - 18 Years to 120 Years   (Adult, Older Adult)
  • Outcome measures - Incidence of major cardiovascular events|Incidence of atrial arrhythmia|Mental health effect of COVID-19 measured by incidence of Generalized Anxiety Disorder (GAD) using Generalized Anxiety Disorder 7-item (GAD-7) Scale|Mental health effect of COVID-19 measured by incidence of depression using Beck Depression Fast Screen Scale|Mental health effect of COVID-19 measured by incidence of Post Traumatic Stress Syndrome (PTSD) using the Post Traumatic Stress Disorder Checklist- Standard Form (PCL-S) scale|Mental health effect of COVID-19 measured by incidence of substance abuse using a baseline use of alcohol survey|Mental health effect of COVID-19 measured by incidence of substance abuse using a baseline use of drugs survey|Mental health effect of COVID-19 measured by incidence of substance abuse using a baseline use of nicotine products survey
NCT05085262 Cardiovascular Disease and Outcomes Among Patients With SARS-CoV-2 Infection (COVID-19) Recruiting Jul/01/2020 Sep/01/2023
  • Alternative id - COVID-19 Study 20-5453
  • Interventions - Diagnostic Test: Bloodwork, Echocardiogram, PET/MRI|Diagnostic Test: Bloodwork, Echocardiogram, MRI
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Toronto General Hospital, UHN, Toronto, Ontario, Canada
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 300
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Prevalence of abnormalities on cardiac MRI|Prevalence of abnormalities on transthoracic echocardiography|Number of participants with abnormal blood biomarkers|Major adverse cardiac and cerebrovascular events (MACCE)|Prevalence of myocardial inflammation on PET/MRI
NCT04422418 Impact of Burnout on Cardiovascular and Immune Biomarkers in Healthcare Professionals - Covid-19 Pandemic in Abu Dhabi Recruiting Jul/01/2020 Dec/31/2020
  • Alternative id - CPRA-2020-034
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates|Mediclinic, Abu Dhabi, United Arab Emirates|Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates|Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 200
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Change from Baseline Burnout at 2-3 months and 6 months|Change from Baseline Cardiovascular Risk Cardiovascular Risk Through Heart Rate Variability Markers at 2-3 months and 6 months|Change from Baseline Through Actigraphy at 2-3 months and 6 months|Change from Baseline Through Sleep Quality at 2-3 months and 6 months|Change from Baseline Cardiovascular Risk Through Fuster-BEWAT score at 2-3 months and 6 months|Change from Baseline Immune Dysfunction at 2-3 months and 6 months|Change from Baseline Cardio-Respiratory Fitness at 2-3 months and 6 months
NCT04255940 2019-nCoV Outbreak and Cardiovascular Diseases Unknown status Jan/20/2020 Apr/30/2020
  • Alternative id - 2019nCoV-CVD
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Affiliated Hospital of Binzhou Medical Universty, Binzhou, Shandong, China|Heze Municipal Hospital, Heze, Shandong, China|Shandong University Qilu Hospital, Jinan, Shandong, China|Jinan Central Hospital, Shandong University, Jinan, Shandong, China|First Hospital Affiliated with Shandong First Medical University, Jinan, Shandong, China|Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China|The Second Hospital of Shandong University, Jinan, Shandong, China|Jining Hospital of Traditional Chinese Medicine, Jining, Shandong, China|Qihe People's Hospital, Qihe, Shandong, China|Affiliated Hospital of Qingdao University Medical College, Qingdao, Shandong, China|Weihai Municipal Hospital, Weihai, Shandong, China|Central Hospital of Zibo, Zibo, Shandong, China
  • Study designs - Observational Model: Case-Only|Time Perspective: Prospective
  • Enrollment - 12000
  • Age - Child, Adult, Older Adult
  • Outcome measures - Cardiovascular Death|Major Adverse Cardiovascular Events|Times From symptom onset to hospital arrival|Anxiety
Export (.csv)